Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
The incidence of dementia is increasing at an alarming rate, and has become a major public health concern. Alzheimer disease (AD) is the most common form of dementia and is characterized by progressive cognitive impairment. In addition to classical neuropathological features such as amyloid plaques and neurofibrillary tangles (NFT), accumulation of activated immune cells has been documented in the AD brain, suggesting a contribution of neuroinflammation in the pathogenesis of AD. Besides cognitive deterioration, non-cognitive symptoms, such as agitation, aggression, depression and psychosis, are often observed in demented patients, including those with AD, and these neuropsychological symptoms place a heavy burden on caregivers. These symptoms often exhibit sudden onset and tend to fluctuate over time, and in many cases, they are triggered by an infection in peripheral organs, suggesting that inflammation plays an important role in the pathogenesis of these non-cognitive symptoms. However, there is no mechanistic explanation for the relationship between inflammation and neuropsychiatric symptoms. Observations from experimental mouse models indicate that alteration of brain blood vessels, especially blood-brain barrier (BBB) dysfunction, may contribute to the relationship. The current review summarizes the results from recent studies on the relationship between inflammation and AD, while focusing on cerebrovascular alterations, which might provide an insight into the pathogenesis of cognitive/non-cognitive symptoms in AD patients and suggest a basis for the development of new therapeutic treatments for these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches
Delrieu, J., Ousset, P. J., Caillaud, C., & Vellas, B. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07458.x · Cited by 139
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 4×
“Brain endothelial cells lining cerebral microvessels act as a physical barrier because they are sealed together by tight junctions, resulting in limited paracellular diffusion, and they have no fenestrations, in contrast to leaky vessels in peripheral organs (Abbott et al., 2006; Ricci et al., 2006). These endothelial…”
BackgroundInfluentialInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328 · cited 1×
“…2009; Zlokovic, 2011), Parkinson disease (Chung et al., 2010; Bartels, 2011), multiple sclerosis (Lassmann et al., 2012; Prineas and Parratt, 2012; Tourdias and Dousset, 2013), and amyotrophic lateral sclerosis (Rodrigues et al., 2012; Garbuzova-Davis and Sanberg, 2014; Winkler et al., 2014), in…”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 2×
“…evidence that BBB dysfunction is associated with the pathogenesis of a variety of neurodegenerative disorders such as AD (Bell and Zlokovic, 2009; Zlokovic, 2011), Parkinson disease (Chung et al., 2010; Bartels, 2011), multiple sclerosis (Lassmann et al., 2012; Prineas and Parratt, 2012;…”
BackgroundDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“…results of recent epidemiological studies have shown that vascular risk factors such as hypertension (Skoog and Gustafson, 2003), diabetes mellitus (Ott et al., 1999; Sato et al., 2011) and atherosclerosis (Takeda et al., 2008) have a significant impact on the progression of AD, although the…”
BackgroundCapillary pericytes regulate cerebral blood flow in health and disease
Hall, C. N., Reynell, C., Gesslein, B., Hamilton, N. B., Mishra, A., Sutherland, B. A., O’Farrell, F. M., Buchan, A. M., Lauritzen, M., & Attwell, D. (2014) · Nature · doi:10.1038/nature13165 · Cited by 1,870 · cited 2×
“BLOOD-BRAIN BARRIER, CEREBROVASCULAR FUNCTION AND NEURODEGENERATIVE DISEASES The entry of most molecules into the central nervous system from the peripheral circulation is strictly regulated by the BBB, and its function and integrity are maintained by the “neurovascular unit”, which is composed of vascular endothelial…”
BackgroundThe Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857 · cited 2×
“Also, it is well recognized that the pathogenesis of AD and vascular dementia overlap Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 171 | 1 (Iadecola, 2010, 2013; Muresanu et al., 2014).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Research works printed but not linked: 3
- Margallo-Lana, 2001, Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments, Int. J. Geriatr. Psychiatry, 16, 39, 10.1002/1099-1166(200101)16:139::aid-gps2693.0.co;2-f · doi:10.1002/1099-1166(200101)16:139::aid-gps2693.0.co;2-f
- Muresanu, 2014, The vascular component of Alzheimer’s disease, Curr. Neurovasc. Res., 11, 168, 10.2174/1567202611666140408105333 · doi:10.2174/1567202611666140408105333
- Thies, 2013, 2013 Alzheimer’s disease facts and figures, Alzheimers Dement., 9, 208, 10.5538/1137-1242.2013.54 · doi:10.5538/1137-1242.2013.54
Cited by
The impact of microglial activation on blood-brain barrier in brain diseases
da Fonseca, A. C. C., Matias, D., Garcia, C., Amaral, R., Geraldo, L. H., Freitas, C., & Lima, F. R. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00362 · Cited by 572
“The major pathological features of this disease are the increased production and deposition of amyloid-β (Aβ) and intracellular accumulation of neurofibrillary tangle composed of hyperphosphorylated tau protein, besides synapse and neuronal loss (Takeda et al., 2014).”
BackgroundNeurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Retinal microglia: Just bystander or target for therapy?
Karlstetter, M., Scholz, R., Rutar, M., Wong, W. T., Provis, J. M., & Langmann, T. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.004 · Cited by 551
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Exercise as an anti-inflammatory therapy for rheumatic diseases—Myokine regulation
Benatti, F. B., & Pedersen, B. K. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.193 · Cited by 474
The neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Montoya, J. G., Holmes, T. H., Anderson, J. N., Maecker, H. T., Rosenberg-Hasson, Y., Valencia, I. J., Chu, L., Younger, J. W., Tato, C. M., & Davis, M. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710519114 · Cited by 402
The Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
Kempuraj, D., Thangavel, R., Selvakumar, G. P., Zaheer, S., Ahmed, M. E., Raikwar, S. P., Zahoor, H., Saeed, D., Natteru, P. A., Iyer, S., et al. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00216 · Cited by 365
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“This in turn leads to Aβ accumulation along brain blood vessels and in the brain leading to vascular inflammation and BBB deterioration (Hsu and Kanoski, 2014; Takeda et al., 2014; Yamazaki and Kanekiyo, 2017).”
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
“Numerous mediators are implicated, including ROS and activation of tissue metalloproteinases, but the dominant pathway to BBB breakdown is inflammation, either central or systemic [331,332].”
BackgroundThe Prefrontal Cortex and Obesity: A Health Neuroscience Perspective
Lowe, C. J., Reichelt, A. C., & Hall, P. A. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2019.01.005 · Cited by 293
Ortega-Martínez, S. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00046 · Cited by 278
Ishida, N., Ishihara, Y., Ishida, K., Tada, H., Funaki-Kato, Y., Hagiwara, M., Ferdous, T., Abdullah, M., Mitani, A., Michikawa, M., et al. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0015-x · Cited by 222
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
“Numerous mediators have been implicated, including reactive oxygen species and activation of tissue metalloproteinases, but the dominant pathway to BBB breakdown is inflammation—central or systemic [3, 4].”
BackgroundKapasi, A., & Schneider, J. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.023 · Cited by 210
Sipilä, P. N., Heikkilä, N., Lindbohm, J. V., Hakulinen, C., Vahtera, J., Elovainio, M., Suominen, S., Väänänen, A., Koskinen, A., Nyberg, S. T., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00144-4 · Cited by 197
Nonalcoholic fatty liver disease is associated with cognitive function in adults
Seo, S. W., Gottesman, R. F., Clark, J. M., Hernaez, R., Chang, Y., Kim, C., Ha, K. H., Guallar, E., & Lazo, M. (2016) · Neurology · doi:10.1212/wnl.0000000000002498 · Cited by 191
Parimisetty, A., Dorsemans, A.-C., Awada, R., Ravanan, P., Diotel, N., & Lefebvre d’Hellencourt, C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0530-x · Cited by 188
Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00119 · Cited by 180
The Possibility of an Infectious Etiology of Alzheimer Disease
Ashraf, G. M., Tarasov, V. V., Makhmutovа, A., Chubarev, V. N., Avila-Rodriguez, M., Bachurin, S. O., & Aliev, G. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1388-y · Cited by 175
Bourgade, K., Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150652 · Cited by 161
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Neutrophil-lymphocyte and platelet-lymphocyte ratios as inflammation markers for bipolar disorder
Kalelioglu, T., Akkus, M., Karamustafalioglu, N., Genc, A., Genc, E. S., Cansiz, A., & Emul, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.110 · Cited by 105
“An association between inflammation and neuropsychiatric disorders, has been reported in recent years including Alzheimer's disease, schizophrenia and BD (Takeda et al., 2014; Feigenson et al., 2014; Ayorech et al., 2015).”
BackgroundDepression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
Colognesi, M., Gabbia, D., & De Martin, S. (2020) · Biomedicines · doi:10.3390/biomedicines8070229 · Cited by 98
Ott, B. R., Jones, R. N., Daiello, L. A., de la Monte, S. M., Stopa, E. G., Johanson, C. E., Denby, C., & Grammas, P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00245 · Cited by 91
Kiyota, T., Machhi, J., Lu, Y., Dyavarshetty, B., Nemati, M., Yokoyama, I., Mosley, R. L., & Gendelman, H. E. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.009 · Cited by 80
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
“It has been observed that AD patients display signs of systemic inflammation [2,15-23], suggesting that systemic inflammation could precede the well-established AD hallmarks i.”
BackgroundAtrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review
Ding, M., & Qiu, C. (2018) · Current Epidemiology Reports · doi:10.1007/s40471-018-0159-7 · Cited by 57
Chang, C.-H., Yu, C.-J., Du, J.-C., Chiou, H.-C., Chen, H.-C., Yang, W., Chung, M.-Y., Chen, Y.-S., Hwang, B., Mao, I.-F., et al. (2018) · Environmental Research · doi:10.1016/j.envres.2017.10.011 · Cited by 54
“The etiology of ADHD is still unclear and is mainly associated with disturbances in dopaminergic activity (Takeda et al., 2014; Wohleb et al., 2014).”
BackgroundAndreadou, E. G., Katsipis, G., Tsolaki, M., & Pantazaki, A. A. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577561 · Cited by 31
Sun, X., Deng, Y., Ge, P., Peng, Q., Soufiany, I., Zhu, L., & Duan, R. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s401385 · Cited by 13
“27– 29 In this study, the decreased levels of several pro-inflammatory factors imply that the neuroprotective effects of DIZE are closely related to the suppression of inflammation.”
Metadata
- Authors
- Takeda, S., Sato, N., & Morishita, R.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-07-29
- Volume
- 6
- Pages
- 171-171
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2150894296
- Cited by
- 223
- References
- 106
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.